Addressing The Future of CAR T-Cell Therapies in Multiple Myeloma
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Previous Post
Expanding Cancer Trial Opportunities Into the “Heart” of the Community
Next Post
Importance of Patient Selection and Future Therapies in Alzheimer Treatment
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago